Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818 010 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
+44 1494 818 010

Zenopa’s help and support throughout my recent recruitment process was invaluable. It was a big decision for me to change careers and it would have been a lot more stressful and daunting without the...
Phil, 2014

Sanofi and Genzyme receive EU approval for Lemtrada

17 September 2013 11:07 in Pharmaceutical Company Product News

Sanofi and Genzyme receive EU approval for LemtradaSanofi and Genzyme have announced that their new multiple sclerosis treatment Lemtrada has been approved by the European Commission.

The drug is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features and has been in active clinical development for more than ten years.

Studies carried out among more than 1,700 patients revealed that Lemtrada can offer significant efficacy benefits compared to currently-available treatment options, with the approval of the product meaning that Genzyme can now plan its European launch.

This comes after another Sanofi/Genzyme multiple sclerosis drug, Aubagio, was also approved by the European Commission last month, with the dual approvals greatly expanding the companies' portfolio in this important medical field.

Genzyme chief executive officer and president Dr David Meeker said: "The approvals of Lemtrada and Aubagio in the EU represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients."ADNFCR-8000103-ID-801638225-ADNFCR

Other news stories from 17/09/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd